Elizabeth Hynes

Elizabeth Hynes

Auto-generated profile, based on publicly available information

Elizabeth Hynes

Laboratory for Molecular Medicine, Partners HealthCare Personalized Medicine, Cambridge, Massachusetts

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2014 in Genetics in Medicine
Verified
Journal Article
Closed access
TPTrevor J Pugh
Trevor J Pugh
MKMelissa A. Kelly
Melissa A. Kelly
SGSivakumar Gowrisankar
Sivakumar Gowrisankar
EHElizabeth Hynes
Elizabeth Hynes
MSMichael A. Seidman
Michael A. Seidman
BFBirgit H. Funke
Birgit H. Funke

1 December 2016 in Genetics in Medicine
Verified
Journal Article
Closed access
DMDiana Mandelker
Diana Mandelker
RSRyan J. Schmidt
Ryan J. Schmidt
AAArunkanth Ankala
Arunkanth Ankala
KGKristin McDonald Gibson
Kristin McDonald Gibson
MBMark Bowser
Mark Bowser
BFBirgit Funke
Birgit Funke

18 April 2022 in Nature Medicine
Verified
Journal Article
Open access
PDF file
LHLimin Hao
Limin Hao
PKPeter Kraft
Peter Kraft
GBGabriel F. Berriz
Gabriel F. Berriz
EHElizabeth D. Hynes
Elizabeth D. Hynes
CKChristopher Koch
Christopher Koch
MLMatthew Lebo
Matthew Lebo
Implementation of polygenic risk scores (PRS) may improve disease prevention and management but poses several challenges: the construction of clinically valid assays, interpretation for individual patients, and the development of clinical workflows and resources to support their use in patient care. For the ongoing Veterans Affairs Genomic Medicine at Veterans Affairs (GenoVA) Study we developed a clinical genotype array-based assay for six published PRS. We used data from 36,423 Mass General Brigham Biobank participants and adjustment for population structure to replicate known PRS–disease associations and published PRS thresholds for a disease odds ratio (OR) of 2 (ranging from 1.75 (95% CI: 1.57–1.95) for type 2 diabetes to 2.38 (95% CI: 2.07–2.73) for breast cancer). After confirming the high performance and robustness of the pipeline for use as a clinical assay for individual patients, we analyzed the first 227 prospective samples from the GenoVA Study and found that the frequency of PRS corresponding to published OR > 2 ranged from 13/227 (5.7%) for colorectal cancer to 23/150 (15.3%) for prostate cancer. In addition to the PRS laboratory report, we developed physician- and patient-oriented informational materials to support decision-making about PRS results. Our work illustrates the generalizable development of a clinical PRS assay for multiple conditions and the technical, reporting and clinical workflow challenges for implementing PRS information in the clinic.

1 April 2012 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
NLNeal K. Lakdawala
Neal K. Lakdawala
BFBirgit H. Funke
Birgit H. Funke
SBSamantha Baxter
Samantha Baxter
ACAllison L. Cirino
Allison L. Cirino
ARAmy E. Roberts
Amy E. Roberts
CHCarolyn Y. Ho
Carolyn Y. Ho

1 July 2016 in Genetics in Medicine
Verified
Journal Article
Open access
TPTrevor J Pugh
Trevor J Pugh
SASami Amr
Sami Amr
MBMark J. Bowser
Mark J. Bowser
SGSivakumar Gowrisankar
Sivakumar Gowrisankar
EHElizabeth Hynes
Elizabeth Hynes
MLMatthew Lebo
Matthew Lebo
To develop and validate VisCap, a software program targeted to clinical laboratories for inference and visualization of germ-line copy-number variants (CNVs) from targeted next-generation sequencing data. VisCap calculates the fraction of overall sequence coverage assigned to genomic intervals and computes log2 ratios of these values to the median of reference samples profiled using the same test configuration. Candidate CNVs are called when log2 ratios exceed user-defined thresholds. We optimized VisCap using 14 cases with known CNVs, followed by prospective analysis of 1,104 cases referred for diagnostic DNA sequencing. To verify calls in the prospective cohort, we used droplet digital polymerase chain reaction (PCR) to confirm 10/27 candidate CNVs and 72/72 copy-neutral genomic regions scored by VisCap. We also used a genome-wide bead array to confirm the absence of CNV calls across panels applied to 10 cases. To improve specificity, we instituted a visual scoring system that enabled experienced reviewers to differentiate true-positive from false-positive calls with minimal impact on laboratory workflow. VisCap is a sensitive method for inferring CNVs from targeted sequence data from targeted gene panels. Visual scoring of data underlying CNV calls is a critical step to reduce false-positive calls for follow-up testing.Genet Med 18 7, 712-719.Genetics in Medicine (2016); 18 7, 712-719. doi:10.1038/gim.2015.156.

1 May 2010 in Genetics in Medicine
Verified
Journal Article
Open access
PDF file
RZRebekah S. Zimmerman
Rebekah S. Zimmerman
SCStephanie Cox
Stephanie Cox
NLNeal K. Lakdawala
Neal K. Lakdawala
ACAllison Cirino
Allison Cirino
DMDebora Mancini-Dinardo
Debora Mancini-Dinardo
BFBirgit Funke
Birgit Funke
Purpose: Genetic tests for the most commonly mutated genes in dilated cardiomyopathy (DCM) can confirm a clinical diagnosis in the proband and inform family management. Presymptomatic family members can be identified, allowing for targeted clinical monitoring to minimize adverse outcomes. However, the marked locus and allelic heterogeneity associated with DCM have made clinical genetic testing challenging. Novel sequencing platforms have now opened up avenues for more comprehensive diagnostic testing while simultaneously decreasing test cost and turn around time. Methods: By using a custom design based on triplicate resequencing and separate genotyping of known disease-causing variants, we developed the DCM CardioChip for efficient analysis of 19 genes previously implicated in causing DCM. Results: The chip's analytical sensitivity for known and novel substitution variants is 100% and 98%, respectively. In screening 73 previously tested DCM patients who did not carry clinically significant variants in 10 genes, 7 variants of likely clinical significance were identified in the remaining 9 genes included on the chip. Compared with traditional Sanger-based sequencing, test cost and turn around time were reduced by ∼50%. Conclusions: The DCM CardioChip is a highly efficient screening test with a projected clinical sensitivity of 26–29%.